CN107184584A - 一种治疗阿尔茨海默病的药物 - Google Patents
一种治疗阿尔茨海默病的药物 Download PDFInfo
- Publication number
- CN107184584A CN107184584A CN201710444718.3A CN201710444718A CN107184584A CN 107184584 A CN107184584 A CN 107184584A CN 201710444718 A CN201710444718 A CN 201710444718A CN 107184584 A CN107184584 A CN 107184584A
- Authority
- CN
- China
- Prior art keywords
- formula
- medicine
- alzheimer disease
- bis
- treating alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 17
- 239000000126 substance Substances 0.000 claims abstract description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 24
- 238000003786 synthesis reaction Methods 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000020510 functional beverage Nutrition 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract description 10
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract description 10
- 230000004083 survival effect Effects 0.000 abstract description 7
- 239000013641 positive control Substances 0.000 abstract description 6
- 230000005779 cell damage Effects 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000004069 differentiation Effects 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 52
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 40
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 28
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 238000003756 stirring Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- UJZYHMZRXGNDFB-UHFFFAOYSA-N 1,3-benzothiazol-5-amine Chemical compound NC1=CC=C2SC=NC2=C1 UJZYHMZRXGNDFB-UHFFFAOYSA-N 0.000 description 4
- 241001122767 Theaceae Species 0.000 description 4
- IMCCZKHIPVEUEI-UHFFFAOYSA-N n,n-difluoroaniline Chemical class FN(F)C1=CC=CC=C1 IMCCZKHIPVEUEI-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229910000474 mercury oxide Inorganic materials 0.000 description 3
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- 102100027831 14-3-3 protein theta Human genes 0.000 description 1
- YEUFXMPHEYKKGP-UHFFFAOYSA-N 3-bromopyrazine-2-carbaldehyde Chemical compound BrC1=NC=CN=C1C=O YEUFXMPHEYKKGP-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
实施例 | 编号 | 结构 | 谱图数据 |
1 | Ⅰa | 1H-NMR (400 MHz, CDCl3) δ:4.39(s,2H), 5.10(s,1H), 6.69(m,1H), 6.80(d,2H),6.98(t,2H), 7.08(t,2H), 7.59(d,2H), 8.07(dd,2H), 8.54(s,1H). 13C-NMR (75MHz, CDCl3) δ: 46.67, 110.08, 110.99, 114.5, 114.61, 118.73, 129.23,139.73, 142.9,143.63, 146.66, 146.98, 147.64, 147.71, 150.08. m/z: 317.12. | |
2 | Ⅰb | 1H-NMR (400 MHz, CDCl3) δ: 4.39(s,2H), 5.41(s,1H), 6.59(d,1H), 6.74(s,1H),6.97(t,2H), 7.58(d,2H), 7.64(d,1H), 8.06(d,2H), 8.53(s,1H), 9.33(s,1H). 13C-NMR (75 MHz, CDCl3) δ: 46.67, 105.19, 110.08, 110.99, 114.5, 116.66,123.06, 124.89, 139.73, 142.9, 143.63, 145.5, 146.66, 146.98, 147.71,150.08, 152.37, 156.08. m/z: 374.08. | |
3 | Ⅰc | 1H-NMR (400 MHz, CDCl3) δ: 4.39(s,2H), 8.08(s,1H), 6.55(d,1H), 6.98(t,2H),7.08(d,1H), 7.51(d,1H), 7.59(d,2H), 8.07(d,2H), 8.54(s,1H). 13C-NMR (75 MHz,CDCl3) δ:45.93, 110.08, 110.99, 114.5, 116.34, 123.81, 124.69, 128.41,130.75, 139.73, 142.9, 143.63, 143.86, 146.66, 146.98, 147.71, 150.08. m/z:385.04. | |
4 | Ⅰd | 1H-NMR (400 MHz, CDCl3) δ: 4.39(s,2H), 4.88(s,1H), 6.98(t,2H), 7.05(d,2H),7.59(d,2H), 8.07(d,2H), 8.61(s,1H). 13C-NMR (75 MHz, CDCl3) δ: 45.8, 110.08,110.99, 112.24, 114.5, 117.33, 128.67, 139.73, 142.9, 143.63, 146.66,146.98, 147.71, 150.08, 152.75. m/z: 431.01 (100.0%). |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710444718.3A CN107184584B (zh) | 2017-06-13 | 2017-06-13 | 一种治疗阿尔茨海默病的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710444718.3A CN107184584B (zh) | 2017-06-13 | 2017-06-13 | 一种治疗阿尔茨海默病的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107184584A true CN107184584A (zh) | 2017-09-22 |
CN107184584B CN107184584B (zh) | 2018-07-13 |
Family
ID=59879639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710444718.3A Expired - Fee Related CN107184584B (zh) | 2017-06-13 | 2017-06-13 | 一种治疗阿尔茨海默病的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107184584B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009037247A1 (en) * | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
CN105102454A (zh) * | 2013-03-29 | 2015-11-25 | 东亚St株式会社 | 作为cetp抑制剂的新型噁唑烷酮衍生物、其制备方法和包含其的药物组合物 |
WO2016080361A1 (ja) * | 2014-11-17 | 2016-05-26 | 日本新薬株式会社 | 経口投与用医薬組成物 |
-
2017
- 2017-06-13 CN CN201710444718.3A patent/CN107184584B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009037247A1 (en) * | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
CN105102454A (zh) * | 2013-03-29 | 2015-11-25 | 东亚St株式会社 | 作为cetp抑制剂的新型噁唑烷酮衍生物、其制备方法和包含其的药物组合物 |
WO2016080361A1 (ja) * | 2014-11-17 | 2016-05-26 | 日本新薬株式会社 | 経口投与用医薬組成物 |
Non-Patent Citations (2)
Title |
---|
ALEX CROWE等: "High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
姚君亮 等: "阿尔茨海默病中Tau蛋白聚集抑制剂的研究进展", 《应用化工》 * |
Also Published As
Publication number | Publication date |
---|---|
CN107184584B (zh) | 2018-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108358973B (zh) | 萘酰亚胺四价铂类化合物、制备方法及其在制备抗肿瘤药物中的应用 | |
CN103735728A (zh) | 地骨皮醇提物、地骨皮甲素及乙素具有神经保护的新用途 | |
CN107556361A (zh) | 裂环羽扇豆烷衍生物及其抗肿瘤用途 | |
CN107629089A (zh) | 高活性的他克林‑铂(ii)配合物及其合成方法和应用 | |
CN103880929A (zh) | 茜草科类型环肽用作为肿瘤转移抑制剂和其制备方法与应用 | |
CN108929329A (zh) | 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物 | |
CN101485666A (zh) | 日蟾毒它灵及其盐化物在制备治疗妇科肿瘤药物中的应用 | |
CN110179809A (zh) | 柴胡皂苷b2在制备抗抑郁症药物中的应用 | |
CN104603133B (zh) | 用于治疗癌症和免疫抑制的组合疗法 | |
CN107184584B (zh) | 一种治疗阿尔茨海默病的药物 | |
CN109810113B (zh) | 一种生物碱化合物及其制备方法与应用 | |
CN107311988A (zh) | 一种治疗阿尔茨海默病的药物 | |
CN105541872B (zh) | 一种邻萘醌衍生物及其制备方法和医药用途 | |
CN104224796B (zh) | 齐墩果烷型三萜类酯衍生物抗神经退行性药物用途 | |
CN103610849B (zh) | 仁青常觉在制备治疗前列腺癌药物中的应用 | |
CN102351881B (zh) | 一种稳定的盐酸左氧氟沙星化合物 | |
CN110078770A (zh) | 一种具有喹啉酮四价铂结构的化合物、制备方法及其在制备抗肿瘤药物中的应用 | |
CN104208074B (zh) | 2α‑羟基原人参二醇在制备肿瘤多药耐药逆转剂中的用途 | |
CN103788058B (zh) | 一种木脂素类化合物及其在防治阿尔茨海默症中的应用 | |
CN104292210B (zh) | 含吡啶的一氧化氮供体类化合物、其制备方法及用途 | |
CN108159035A (zh) | 肉桂酸类衍生物的新用途 | |
Li et al. | Design, Synthesis, and Neuroprotective Effects of Novel Cinnamamide-Piperidine and Piperazine Derivatives | |
CN104370792B (zh) | 奥拉西坦化合物 | |
CN102895222B (zh) | 5-(3,4-亚甲二氧基苯基)-2e,4e戊二稀酸正丙胺酰胺在制备治疗神经疾病产品中的应用 | |
CN105085348B (zh) | 一种苯甲酸硫酯类化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhao Lei Inventor after: Zhao Fengqing Inventor after: Li Faqun Inventor before: Ju Defeng |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180522 Address after: 262500 4138 Linglong South Road, Qingzhou City, Weifang, Shandong province (Weifang Yi Du Central Hospital) Applicant after: Zhao Lei Address before: 262612 Wolong Town, Linqu County, Weifang, Shandong Applicant before: Ju Defeng |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180713 Termination date: 20210613 |
|
CF01 | Termination of patent right due to non-payment of annual fee |